ARA-290 (Cibinetide) in South Africa: The Nerve-Repair Peptide, Honestly Reviewed

Most of the peptide conversation in South Africa is about healing tendons, gut lining and joints. ARA-290 — also called cibinetide — sits in a different lane: it's studied for damaged small nerve fibres and the burning, tingling neuropathic pain that comes with them. It's one of the few tissue-repair peptides with placebo-controlled human trial data, which makes it worth understanding properly.¹

What ARA-290 actually is

ARA-290 is an 11-amino-acid peptide engineered from a region of the erythropoietin (EPO) molecule. Crucially, it was designed to keep EPO's tissue-protective, anti-inflammatory signalling while dropping the effect on red-blood-cell production — so it does not raise haematocrit the way EPO does.² It works by activating the innate repair receptor (a heteroreceptor complex of the EPO receptor and the beta-common receptor) that switches on in injured and inflamed tissue.

What the human evidence shows

This is where ARA-290 stands apart from most 'healing' peptides — there are actual randomised, placebo-controlled trials, mostly in sarcoidosis-associated small-fibre neuropathy:

• Dahan et al. (2013): ARA-290 improved neuropathic symptoms and increased corneal nerve fibre density in patients with sarcoidosis-associated small-fibre neuropathy.¹
• Culver et al. (2017), Phase 2b: 64 patients, daily subcutaneous dosing for 28 days. 4 mg/day produced roughly a 23% increase in corneal nerve fibre abundance versus placebo, alongside reduced pain and improved function.³
• Type 2 diabetes with neuropathy (Phase 2): 4 mg/day for 28 days was associated with improvements in neuropathic symptom scores and some metabolic markers.⁴

The signal — nerve fibre regrowth measured objectively by corneal confocal microscopy — is genuinely interesting because it's a structural endpoint, not just a symptom questionnaire. That said, be honest about the ceiling: trials were small, short (28 days), and concentrated in sarcoidosis and diabetes. No large Phase 3 replication was completed before the developer, Araim Pharmaceuticals, wound down.³

Research dosing seen in the literature

Dosing in the published trials was remarkably consistent, which is unusual for this space:

• Standard trial dose: 4 mg subcutaneously, once daily
• Trial duration: 28-day courses in most studies
• Route: subcutaneous self-injection
• Dose range tested: 1-8 mg/day, with 4 mg emerging as the effective sweet spot

Safety signal

In the trials, ARA-290 was generally well tolerated, and — by design — it did not meaningfully raise haematocrit, which is the main safety concern with EPO itself.² The honest caveat is that 28-day trials in small groups can't tell you much about long-term or off-label use. Anyone considering it should be doing so with a clinician who understands both the peptide and the underlying nerve condition.

Who's actually asking about it in South Africa

In our Cape Town clinics the ARA-290 questions come from a specific crowd: people with diagnosed small-fibre neuropathy, diabetic neuropathic pain, or neuropathy secondary to sarcoidosis — not the general recovery audience. That's the right framing. ARA-290 is a targeted research compound for nerve pathology, not a stack-filler.

If you're going to source it, demand the same standards

The sourcing rules don't change just because the target tissue does:

• Third-party HPLC + mass-spec COA matched to the vial lot number
• ≥99% purity threshold
• Cold-chain shipping for lyophilised vials, reconstituted only with documented bacteriostatic water
• A clinician in the loop — neuropathy needs a diagnosis and monitoring, not self-experimentation

If a supplier can't produce a COA on request, walk away — the same rule we apply to every peptide.⁵

Reasonable expectations

The trial data suggests ARA-290's benefits build over a 28-day course and centre on nerve-fibre density and neuropathic symptoms — not energy, body composition or general 'wellness'. If your problem isn't nerve-related, this almost certainly isn't your peptide. If it is, ARA-290 is one of the better-evidenced options in a field that mostly runs on animal data and anecdote.